Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Elena S. Koltun, Mallika Singh et al.|Nature|2024Cited by 319
Massively parallel pooled screening reveals genomic determinants of nanoparticle deliveryNatalie Boehnke, Paula T. Hammond, Joelle P. Straehla et al.|Science|2022Cited by 195
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N. Wasko, Miroslav Sekulic, Jingjing Jiang et al.|Nature|2024Cited by 175
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunityChristina K. Baumgartner, Joshua H. Decker, Carey Backus et al.|Nature|2023Cited by 170
A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumorsCaroline E. Weller, David Wildes, G. Leslie Burnett et al.|Science|2025Cited by 31